Literature DB >> 25744618

Psychedelics not linked to mental health problems or suicidal behavior: a population study.

Pål-Ørjan Johansen1, Teri Suzanne Krebs2.   

Abstract

A recent large population study of 130,000 adults in the United States failed to find evidence for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and mental health problems. Using a new data set consisting of 135,095 randomly selected United States adults, including 19,299 psychedelic users, we examine the associations between psychedelic use and mental health. After adjusting for sociodemographics, other drug use and childhood depression, we found no significant associations between lifetime use of psychedelics and increased likelihood of past year serious psychological distress, mental health treatment, suicidal thoughts, suicidal plans and suicide attempt, depression and anxiety. We failed to find evidence that psychedelic use is an independent risk factor for mental health problems. Psychedelics are not known to harm the brain or other body organs or to cause addiction or compulsive use; serious adverse events involving psychedelics are extremely rare. Overall, it is difficult to see how prohibition of psychedelics can be justified as a public health measure.
© The Author(s) 2015.

Entities:  

Keywords:  Psychedelic; epidemiology; hallucinogen; public health; suicide

Mesh:

Substances:

Year:  2015        PMID: 25744618     DOI: 10.1177/0269881114568039

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  47 in total

Review 1.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 2.  Neurotoxicology Syndromes Associated with Drugs of Abuse.

Authors:  Rachel A Caplan; Jonah P Zuflacht; Jed A Barash; Corey R Fehnel
Journal:  Neurol Clin       Date:  2020-11       Impact factor: 3.806

3.  Role of psilocybin in the treatment of depression.

Authors:  Ananya Mahapatra; Rishi Gupta
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-27

4.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

5.  Clinical potential of psilocybin as a treatment for mental health conditions.

Authors:  Jeremy Daniel; Margaret Haberman
Journal:  Ment Health Clin       Date:  2018-03-23

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

7.  Psilocybin, psychological distress, and suicidality.

Authors:  Peter S Hendricks; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-09       Impact factor: 4.153

8.  Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings.

Authors:  Matthias Forstmann; Daniel A Yudkin; Annayah M B Prosser; S Megan Heller; Molly J Crockett
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-21       Impact factor: 11.205

Review 9.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

Review 10.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.